These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion’s untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.
Similar Posts
Study of Sex Differences in the Clinical Evaluation of Medical Products
This guidance provides recommendations for increasing enrollment of females in clinical trials, analyzing and interpreting sex-specific data, and including sex-specific information in regulatory submissions of medical productsFDA Holds Meeting with States on Importation of Lower Cost Drugs
FDA held a meeting with several states to discuss the section 804 importation program (SIP), which allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs to the American consumer.Shilpa Medicare Limited – 11/21/2025
Shilpa Medicare Limited – 11/21/2025. Country: India. Record Type: 483Medi-Fare Drug Pharmaceutical Compounding LLC. Blacksburg, SC. 483 issued 06/06/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 06/06/2025
Short Title (70 char) Medi-Fare Drug Pharmaceutical Compounding LLC. Blacksburg, SC. 483 issued 06/06/2025
FEI Number 3009925820
Firm Name Medi-Fare Drug Pharmaceutical Compounding LLC
Record Type 483SiluetaYa Recalls Tejocote Product Because of Possible Health Risk
SiluetaYa is recalling its tejocote root because FDA analysis has determined that the products appear to be Thevetia peruviana, or yellow oleander. All parts of the yellow oleander plant are known to contain cardiac glycosides, which are highly toxic to humans and animals. Ingestion of yellow oleandCitalopram (marketed as Celexa) Information
Citalopram (marketed as Celexa) Information